Saturday 17 October 2026
Export MDGL’s income statement to Excel — free account
Madrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.
449.74
10.07
−2.19%
Follow MDGL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (53.31%) | (49.35%) | (42.49%) | (41.22%) |
+8 more TTM periods Free account |
|
| (28.77%) | (27.83%) | (25.05%) | (23.74%) | ||
ROIC |
(787.33%) | (297.52%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(38.86%) | (36.32%) | (30.77%) | (30.17%) | |
Average Days of Receivables |
54.67 | 60.38 | 51.21 | 55.83 | |
Free Cash Flow per Share |
(7.08) | (9.39) | (8.65) | (7.36) | |
Free Cash Flow |
(206.28) | (272.61) | (193.99) | (165.54) | |
Capital Expenditures |
(8.57) | (4.51) | (4.44) | (4.96) | |
| Other line items | |||||
Cash ROIC |
(12.11%) | (16.02%) | (10.05%) | (7.96%) | |
Accounts Receivable Turnover |
9.46 | 9.10 | 10.18 | 10.30 | |
Accounts Payable Turnover |
3.02 | 1.53 | 1.21 | 0.77 | |
Inventory Turnover |
1.34 | 0.94 | 1.03 | 0.90 | |
Average Days of Payables |
115.13 | 282.77 | 317.74 | 466.74 | |
Days of Inventory on Hand |
331.53 | 521.21 | 486.52 | 719.89 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
38.17% | 40.00% | 40.54% | 40.22% | |
Selling, General and Administrative Expense of Revenue |
78.43% | 80.75% | 84.91% | 96.55% | |
Share Based Compensation of Revenue |
9.46% | 9.82% | 10.24% | 12.15% | |
Interest Coverage |
(10.24) | (11.68) | (13.45) | (17.56) | |
Operating CF/Net income |
0.61 | 0.87 | 0.66 | 0.56 | |
Depreciation/Fixed assets |
0.64 | 0.83 | 4.22 | 1.65 | |
Capex/Depreciation |
(1.16) | (0.67) | (0.70) | (1.03) | |
Revenue per Share |
44.05 | 39.01 | 42.72 | 32.94 | |
Operating CF per Share |
(6.78) | (9.23) | (8.45) | (7.14) | |
Capex per Share |
(0.29) | (0.16) | (0.20) | (0.22) | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.01 |
Columns are period end dates